

Chemo-enzymatic fluorination of unactivated organic compounds

Andrea Rentmeister¹, Frances H Arnold¹ & Rudi Fasan^{1,2}

Fluorination has gained an increasingly important role in drug discovery and development. Here we describe a versatile strategy that combines cytochrome P450-catalyzed oxygenation with deoxyfluorination to achieve mono- and polyfluorination of nonreactive sites in a variety of organic scaffolds. This procedure was applied for the rapid identification of fluorinated drug derivatives with enhanced membrane permeability.

Fluorination has become an increasingly important tool for fine-tuning the pharmacokinetic and pharmacological properties of drugs and lead compounds, thus leading to a growing number of fluorine-containing pharmaceuticals on the market¹. Benefits of hydrogen-to-fluorine substitutions arise principally from their effects on membrane permeability, metabolic stability and/or receptor-binding properties of bioactive molecules^{1–3}. In many cases, fluorination of much less active precursors has yielded potent drugs with enhanced bioavailability, reduced toxicity or improved affinity for the target receptor³. A number of methods have been developed for synthesis of fluorinated compounds^{4,5}, including asymmetric fluorination strategies^{6,7} and chemo-enzymatic approaches^{8,9}. Despite this progress, selective incorporation of fluorine at non-activated or weakly reactive sites of a target scaffold remains difficult and may require several synthetic steps.

Here we describe a facile two-step procedure for the selective fluorination of one or more non-activated sites in an organic molecule. This approach couples the exceptional ability of cytochrome P450 monooxygenases to selectively insert oxygen into nonreactive C-H bonds with a deoxyfluorination reaction in which the newly generated hydroxyl group is substituted by fluorine by means of a nucleophilic fluorinating reagent (Fig. 1). To test the validity of this approach, we targeted various classes of small molecules, including marketed pharmaceuticals (Supplementary Fig. 1 online). For the enzymatic step, we used variants of the bacterial long-chain fatty acid hydroxylase P450_{BM3} from *Bacillus megaterium*. Catalytic self-sufficiency, high monooxygenase activity and high expression level in *Escherichia coli* render P450_{BM3} an attractive catalyst for *in vitro* and *in vivo* applications¹⁰. For this work, we assembled a panel of 96 P450s derived from a catalytically promiscuous P450_{BM3} variant identified in the early stages of the directed evolution of a proficient alkane monooxygenase¹¹. These variants were found to exhibit good activity and various degrees of selectivity on alkanes and non-alkane substrates¹¹.

The first group of test molecules (1, 2 and 3; Fig. 2a,b) contain a cyclopentenone moiety found in several natural products (for example, jasmonoids, cyclopentanoid antibiotics and prostaglandins). The synthesis and functionalization of these scaffolds is not trivial¹². The activities of the enzymes toward these substrates were probed in multiwell format using gas chromatography and GC-MS (Fig. 2a). Depending on the substrate, approximately 30 to 50% of the 96 enzyme variants displayed useful activity (>800 turnovers), while 30 to 50% of this active subset showed moderate to excellent regioselectivity (50–100%). The most active and selective variants were applied in preparative scale reactions (100–300 mg) using ~0.05 mol% catalyst. Compared with 96-well plate reactions, three to four times higher turnover numbers could be obtained using purified enzyme and longer reaction times (24–48 h). After flash chromatography purification, the hydroxylated products were subjected to deoxyfluorination using the common nucleophilic fluorinating agent diethylaminosulfur trifluoride (DAST, 4). The identities and purities of the fluorinated products were established by GC-MS, HRMS and ¹H, ¹³C and ¹⁹F NMR (Supplementary Methods online). Using this strategy, we were able to target two to three different sites on each substrate with good to excellent regioselectivity (55–100%), thereby affording the fluorinated derivatives 5, 6, 7, 8, 9, 10 and 11 with yields of up to 80% over the two steps.

Next we tested this fluorination strategy on a methylester pro-drug of the anti-inflammatory drug ibuprofen (12; Fig. 2a,c). Although preparation of α -fluoro derivatives of this compound is straightforward¹³, incorporating fluorine atoms in the poorly reactive isobutyl group is not. The general procedure described above enabled us to identify two chemo-enzymatic routes to achieve this goal in a selective (position 1, 75%; position 2, 100%) and efficient manner (yields over two steps for 15 and 16 were 62% and 84%, respectively) and at preparative scales (150–200 mg).




Figure 1 Cytochrome P450-based approach for selective fluorination of organic molecules. (a) Hydroxyl groups are introduced (via direct oxygen insertion) or exposed (via hydroxylation-demethylation) in a target scaffold using a P450 monooxygenase and substituted for fluorine using a nucleophilic fluorinating agent. DF, deoxyfluorination. (b) Different fluorinated derivatives of a molecule of interest are obtained using P450 variants with different regioselectivities.

¹Department of Chemistry and Chemical Engineering, California Institute of Technology 210-41, 1200 East California Boulevard, Pasadena, California 91125, USA.

²Present address: Department of Chemistry, University of Rochester, Hutchison Hall, RC Box 270216, Rochester, New York 14627, USA. Correspondence should be addressed to R.F. (fasan@chem.rochester.edu).

Received 11 August; accepted 27 October; published online 16 November 2008; doi:10.1038/nchembio.128




Figure 2 Chemo-enzymatic fluorination of organic molecules. **(a)** Screening of P450 library in 96-well format. Reactions were carried out in the presence of the substrate, P450 enzyme from cell lysate and a glucose-6-phosphate dehydrogenase-based NADPH regeneration system. TON, turnover number. Standard error is within 15%. WT, wild-type P450_{BM3}. **(b)** Selective fluorination of cyclopentenone derivatives. Reagents and conditions: (i) **1**, 0.04 mol% var-H3, 88%; (ii) DAST (1.2 equiv), CH₂Cl₂, -78 °C, 12 h, 90% (20% ee); (iii) **1**, 0.04 mol% var-G6, 45%; (iv) DAST (1.2 equiv), CH₂Cl₂, -78 °C, 12 h, 85%; (v) **2**, 0.05 mol% var-H3, 85%; (vi) DAST (1.3 equiv), CH₂Cl₂, -78 °C, 12 h, 92% (78% ee); (vii) **2**, 0.05 mol% var-G4, 42%; (viii) DAST (1.5 equiv), CH₂Cl₂, -78 °C, 12 h, 89%; (ix) **3**, 0.05 mol% var-D10, 69%; (x) DAST (1.2 equiv), CH₂Cl₂, -78 °C, 3 h, 88% (dr 1:8.5; major, 5% ee; minor, 71% ee); (xi) **3**, 0.05 mol% var-G4, 62%; (xii) DAST (1.2 equiv), CH₂Cl₂, -78 °C, 5 h, 92% (dr 4:96; major, 0% ee; minor, 57% ee); (xiii) **3**, 0.07 mol% var-G5, 32%; (xiv) DAST (1.2 equiv), CH₂Cl₂, -78 °C, 5 h, 90% (dr not measurable). **(c)** Selective mono- and difluorination of pro-drug ibuprofen methylester. Reagents and conditions: (i) 0.1 mol% var-B4, 72%; (ii) DAST (1.4 equiv), CH₂Cl₂, -78 °C, 12 h, 86% (dr 1:3.2; major, 19% ee; minor, 44% ee); (iii) 0.05 mol% var-G4, 88%; (iv) DAST (1.4 equiv), CH₂Cl₂, -78 °C, 12 h, 95%; (v) 0.06 mol% var-B2, 93%; (vi) DAST (1.2 equiv), CH₂Cl₂, -78 °C, 12 h, 98% (dr 1:3.7; major, 9% ee; minor, 9% ee). All experimental procedures are described in detail in **Supplementary Methods**. The sequences of the P450 variants are described in **Supplementary Table 2** online. Yields refer to the isolated products. Enantiomeric excess values were determined by chiral gas chromatography analysis.

We then investigated whether two sequential chemo-enzymatic transformations could be used to fluorinate multiple sites of the same molecule. P450 variant B4 (var-B4)—which was used to convert **12** to **13**—was found to retain comparable activity on **16**, providing a possible route to the desired **17** intermediate. Re-screening of **12**-active variants on **16**, however, led to the identification of a more suitable candidate, var-B2, with higher activity than var-B4 toward **16** and excellent (100%) 2-regioselectivity. Using var-B2, the synthesis of fluorohydroxy derivative **17** was afforded in higher yields (93% versus 72% for conversion of **12** to **13**) and required less catalyst (0.06 mol% versus 0.1 mol% for conversion of **12** to **13**). **17** was then converted quantitatively to the desired difluoroderivative **18**.

The value of the present approach as synthetic tool for asymmetric fluorination was also examined. In the absence of anchimeric group participation, the deoxofluorination reaction generally preserves the enantiopurity of the enzymatic products through inversion of configuration¹⁴. Chiral gas chromatography analysis showed appreciable stereoselectivity during preparation of **7** (78% enantiomeric excess (ee), **9** (diastomeric ratio (dr) 1:8.5), **10** (dr 4:96), **15** (dr 1:3.2) and **18** (dr 1:3.7) (see **Supplementary Figs. 2–6** online for gas chromatography traces). We then extended our previous investigations on 2-phenylacetic acid esters¹⁵, carrying out the asymmetric synthesis of the corresponding 2-fluoro-2-arylacetic acid derivatives at 100-mg scale (**19a**, **20a**, **21a**, **22a** and **23a**; **Supplementary Table 1** online). In this case, up to 89% ee in up to 60% yield (two steps) was achieved.

P450-catalyzed hydroxylation of methoxy groups leads to exposure of a free hydroxyl group through decomposition of the hemiacetal produced and release of formaldehyde. We reasoned that our chemo-enzymatic strategy could be extended to substitute a methoxy group for fluorine, a challenging transformation for traditional chemical methods. This approach was first tested on the 5-phenyloxazoline derivative **24** (**Fig. 3a,b**). The demethylation activities of the P450 variants could be easily assessed using a colorimetric screen (**Fig. 3a**). The most active variants from the screen were further analyzed with respect to the regioselectivity of oxidation using GC-MS. The highly selective P450 variant var-H1 (95%) was thus applied in combination with deoxofluorination to afford the desired fluorine-containing compound (**26**).

The same approach was tested on a set of derivatives of the synthetically important building block Corey lactone (**Fig. 3c**). The use of various Corey lactones (**27a**, **28a** and **29a**) enabled us to investigate the tolerance of the enzymatic transformation to structural variations within the target scaffold. Based on the colorimetric screen, 30 variants displayed activity on at least one Corey lactone (12 on **27a**, 17 on **28a**, 5 on **29a**). Twelve variants were found to accept both **27a** and **28a**, five were found to accept **28a** and **29a** and five were found to accept **27a** and **29a**. Notably, four variants (~10% of the Corey lactone-active variants) could be used to activate the substrate for subsequent fluorination, regardless of the size of the variable substituent. Using the most active and selective enzymes toward each of the Corey lactones, the desired fluorine-containing compounds **27c**, **28c** and **29c** were synthesized and isolated.




Figure 3 Chemo-enzymatic methoxy-to-fluorine transformation. **(a)** Screening of P450 demethylation activities using a Purpald-based assay for detection of formaldehyde formation in 96-well plate format. Standard error is within 15%. WT, wild-type P450_{BM3}; OD₅₅₀, optical density at 550 nm. **(b)** Methoxy-to-fluorine transformation in a 5-phenyloxazoline derivative. Reagents and conditions: (i) 0.1 mol% var-H1, KPi pH 8.0, room temperature, 48 h, 92%; (ii) DAST (1.0 equiv), CH₂Cl₂, 0 °C, 12 h, 40%. **(c)** Methoxy-to-fluorine transformation in Corey lactone derivatives. All experimental procedures are described in detail in **Supplementary Methods**. The sequences of the P450 variants are described in **Supplementary Table 2**. Yields refer to the isolated products.

combined for selective fluorination of multiple sites on the same molecule. A common strategy for improving drugs' *in vivo* half-lives involves blocking the sites in the molecule that are susceptible to attack by human P450s with fluorine substituents^{2,3}. It is worth noting that fluorination of position 2 in **15** and **18** would prevent one of the major P450-dependent routes of ibuprofen metabolism in humans¹⁹. An added advantage of this approach is thus to enable fluorination of metabolically vulnerable sites in the target molecule. We expect this procedure to find utility in the rapid identification of drug or lead compound derivatives with improved chemophysical or biological properties and in the preparation of fluorinated synthons for chemical synthesis or fragment-based drug discovery programs.

Note: Supplementary information and chemical compound information is available on the Nature Chemical Biology website.

ACKNOWLEDGMENTS

We are grateful to M. Shahgholi for assistance with the LC-MS and HRMS analyses. This work was supported by US National Institutes of Health grant GM068664 and US Department of Agriculture grant 2006-35505-16660 to F.H.A. and by the Jacobs Institute (Caltech). A.R. acknowledges the Deutsche Forschungsgemeinschaft for financial support.

AUTHOR CONTRIBUTIONS

R.F. and F.H.A. conceived the project; R.F. and A.R. performed the experiments; all authors discussed the results; R.F. wrote the paper with help and edits from F.H.A. and A.R.

COMPETING INTERESTS STATEMENT

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturechemicalbiology/>.

Published online at <http://www.nature.com/naturechemicalbiology/>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

Ibuprofen has recently shown promising activity against amyloidogenic diseases¹⁶. Anti-amyloidogenic drugs with high brain permeability are intensively sought¹⁶. We tested **15**, **16** and **18** in a membrane permeability assay that mimics the composition of the blood brain barrier (BBB). While **12** has only modest BBB-crossing potential, monofluorinated **15** and **16** and difluorinated **18** exhibit, respectively, very good and excellent membrane permeability properties (effective permeability value $> 10 \times 10^{-6} \text{ cm s}^{-1}$; **Supplementary Fig. 7** online), which demonstrates how this procedure could be applied to rapidly screen various hydrogen-to-fluorine substitutions in a target molecule for improvement in chemophysical or biological properties.

This chemo-enzymatic approach has proven useful for fluorinating 13 of the 16 molecules tested (see **Supplementary Fig. 1**). The molecular weight of these compounds ranges between 110 and 450 Da. About 75% of commercial drugs fall within this window¹⁷. Much larger molecules may have restricted access to the enzyme's active site, representing suboptimal targets for this chemo-enzymatic approach. As the P450_{BM3} active site is largely hydrophobic, highly polar compounds may also be poor substrates. Difficulties were mostly associated with solubilization of the substrate in aqueous media (**30**) or with the occurrence of side reactions—in particular elimination—during the deoxofluorination transformation (hydroxylated **31** and **32**), which prevented isolation of the enzymatic and fluorinated products, respectively, in satisfactory yields. These issues could be addressed, however, by using P450_{BM3} variants with increased activity in the presence of organic co-solvent¹⁸ and applying milder nucleophilic fluorination methods.

Overall, the described methodology extends the range of available tools for selective fluorination. Importantly, it provides a concise solution to selective incorporation of fluorine atoms at relatively unreactive sites in a variety of organic molecules and at a preparative scale. The regio- and stereoselectivity of this chemical transformation can be altered by engineering the protein catalyst. This strategy is versatile, as the same chemo-enzymatic route can be applied to various structurally related scaffolds, and more chemo-enzymatic transformations can be

- Muller, K., Faeh, C. & Diederich, F. *Science* **317**, 1881–1886 (2007).
- Park, B.K., Kitteringham, N.R. & O'Neill, P.M. *Annu. Rev. Pharmacol. Toxicol.* **41**, 443–470 (2001).
- Bohm, H.J. *et al. ChemBioChem* **5**, 637–643 (2004).
- Kirsch, P. *Modern Fluoroorganic Chemistry* (Wiley-VCH, Weinheim, Germany, 2004).
- Shimizu, M. & Hiyama, T. *Angew. Chem. Int. Ed.* **44**, 214–231 (2005).
- Ma, J.A. & Cahard, D. *Chem. Rev.* **104**, 6119–6146 (2004).
- Bobbio, C. & Gouverneur, V. *Org. Biomol. Chem.* **4**, 2065–2075 (2006).
- Günter, H. *J. Fluor. Chem.* **125**, 875–894 (2004).
- Iacazio, G. & Réglér, M. *Tetrahedron Asymmetry* **16**, 3633–3639 (2005).
- Warman, A.J. *et al. Biochem. Soc. Trans.* **33**, 747–753 (2005).
- Fasan, R., Mehareenna, Y.T., Snow, C.D., Poulos, T.L. & Arnold, F.H. *J. Mol. Biol.* **383**, 1069–1080 (2008).
- Mikolajczyk, M., Mikina, M. & Zurawinski, R. *Pure Appl. Chem.* **71**, 473–480 (1999).
- Fujisawa, H., Fujiwara, T., Takeuchi, Y. & Omata, K. *Chem. Pharm. Bull. (Tokyo)* **53**, 524–528 (2005).
- Singh, R.P. & Shreeve, J.M. *Synthesis* **17**, 2561–2578 (2002).
- Landwehr, M. *et al. J. Am. Chem. Soc.* **128**, 6058–6059 (2006).
- Leuchtenberger, S., Beher, D. & Weggen, S. *Curr. Pharm. Des.* **12**, 4337–4355 (2006).
- Feher, M. & Schmidt, J.M. *J. Chem. Inf. Comput. Sci.* **43**, 218–227 (2003).
- Wong, T.S., Arnold, F.H. & Schwaneberg, U. *Biotechnol. Bioeng.* **85**, 351–358 (2004).
- Hamman, M.A., Thompson, G.A. & Hall, S.D. *Biochem. Pharmacol.* **54**, 33–41 (1997).